Slide 1: Company Overview April 2015
& CorMedix” Company Overview April 2015
Slide 2: Key Investment Highlights
Key Investment Highlights oo First-in-Class Product with Significant Unmet Need Approved for Use in Europe and Other Geographies De-Risked Path for US. Approval Near-Term Opportunities Confidential Neutrolin® is effective in reducing catheter-related blood stream infections (CRBSI) and thrombosis by
Slide 3: CorMedix Profile
CorMedix Profile CorMedix is a global biopharmaceutical company focused on the prevention and treatment of infectious diseases and thrombosis in both acute and chronic care settings — The Company has a global IP portfolio which includes 23 issued patents Neutrolin® is CorMedix’s lead product — Neutr
Slide 4: Overview of Neutrolin®
Overview of Neutrolin® Neutrolin® is a first-in-class “catheter lock” solution undergoing cli ical evaluation in the U.S. as a drug to prevent biofilm development thereby significantly decreasing thrombosis _and infection Key Components * Taurolidine 1.35% (anti-infective) * Heparin 1,000 u/ml (anti
Slide 5: The Opportunity
The Opportunity Despite recent improvements and initiatives in infection hygiene, biofilm develops very quickly and can lead to life-threatening complications, costing the US healthcare system approximately $5 billion annually icantUnmetNeed | [ Stages of Biofilm Development } * 1.7 million infectio
Slide 6: CorMedix Estimated Timeline
CorMedix Estimated Timeline September 2014: January2015: | March/April 2015: Received CE mark FDA granted Pharma economic label expansion to analysi cover Oncology, Infectious Abstract and poster TPN and ICU Disease Product presentations at NKF indications for designationto (Dallas) and VAS. Neutrol
Slide 7: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMe